BioHealth Innovation
If you are having trouble viewing this email, please click here

February 20, 2019


Charles J. Andres, Associate, Intellectual Property with Wilson Sonsini, Goodrich & Rosati (WSGR), joins Rich Bendis for BioTalk to discuss his career, the opportunities/challenges in this industry, and WSGR's role in the BioHealth Capital

Charles Andres, Ph.D., RAC, is an associate in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati. He focuses on patent prosecution, strategic patent counseling, IP due diligence, drug and medical device FDA regulatory counseling, invalidity and non-infringement opinions, life-cycle management, Supreme Court and Federal Circuit amicus briefs, and related business matters.Charles Andres, Ph.D., RAC, is an associate in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati. He focuses on patent prosecution, strategic patent counseling, IP due diligence, drug and medical device FDA regulatory counseling, invalidity and non-infringement opinions, life-cycle management, Supreme Court and Federal Circuit amicus briefs, and related business matters.

Charlie has significant experience drafting patent applications, prosecuting patent applications in the U.S. and abroad, and evaluating the claims of issued patents. He has won cases before the Board of Patent Appeals and Interferences by brief and on oral argument. Patents Charlie has obtained have been listed in the Orange Book and asserted against a generic pharmaceutical manufacturer, and he has drafted and filed multiple applications for patent term extension. Companies he has obtained patents for have been sold for a cumulative total of approximately $4 billion.

Listen now on iTunes Google Play , and TuneIn

Read More



Submit your application by March 1st for a chance to be named

‘the company with the most commercial potential’

at the BioHealth Capital Region Forum 

Deadline for entries is March 1, 2019

Finalists will be announced March 21, 2019

Present at BioHealth Capital Region Forum April 9, 2019.

Finalists will have a chance to win the grand prize by presenting in front of a panel of world-class judges.


Grand Prize provided by WSGR $10,000

Visibility in front of hundreds of industry leaders and prominent industry funding experts and executives.


Product, Technical Feasibility, Marketing/Strategy, Leadership Team, Financial/Projection

Read More

SAVE THE DATE - 2019 BioHealth Capital Region Forum

April 8 + 9, 2019

One MedImmune Way, Gaithersburg, MD 20878

This invitation-only event is free for executive level biotech leaders and is presented by BioHealth Innovation, VirginiaBio, Maryland Tech Council, University System of Maryland, Children’s National Health Network, HemoShear, GSK, BeneVir, Quality Biological, Johns Hopkins University and AstraZeneca. Maryland, Virginia, and Washington, DC set the bar high for biotech innovation. So please join us for our Annual BioHealth Capital Region Forum that will highlight the accomplishments of today and chart our successes of tomorrow.

Register at

For more information about our speakers and event schedule, please visit

Read More

AstraZeneca retires MedImmune brand - Washington Business Journal

But not everything is expected to change at the Gaithersburg campus.

Read More

AURP's Brian Darmody looks to make College Park office a hub for research parks - Baltimore

Among the organizations taking glass-enclosed office space in the recently opened WeWork at University of Maryland College Park is an organization looking to promote research parks that cluster minds in science and business.

Read More

Are the big corporate venture arms retreating? - Evaluate

At the beginning of this decade, when the fallout of the financial crash was still being felt and traditional venture firms were struggling to raise money, the investment arms of big pharma companies stepped in to fill a funding gap that was starving start-ups. Fast forward to the current period of plenty and, while corporate cash is no longer quite so crucial to the ecosystem, many of these units remain enthusiastic backers of early-stage science.

Read More

American Gene Technologies Signs Research Agreement with NIAID for Experimental HIV/AIDS Cure Strategy | American Gene Technology

American Gene Technologies (AGT) recently signed a Research Collaboration Agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, for research studies on AGT’s cell and gene therapy for HIV/AIDS. AGT uses its proprietary, genetically modified, autologous cell product (AGT103-T) to reconstitute the immune response against HIV with the goal of reducing persistent viral reservoirs and achieving sustained virologic remission in infected individuals in the absence of antiretroviral therapy. Under this collaboration agreement, NIAID researchers will study the mechanism of action for AGT103-T to define its potential impacts on HIV disease.

Read More

BioHealth Innovation Entrepreneur-in-Residence Feedback - Feb. 27th

Are you a start-up in Maryland, DC or Virginia seeking feedback on your biohealth business idea, pitch deck, or commercialization plan?  Sign up now to schedule your feedback session with BHI Entrepreneurs in Residence next Wednesday, February 27th.  (Future sessions scheduled for 3/20 and 5/22.)  Pre-registration is required; sign up here ("EIR resource" at BHI).  For questions/more information, contact BHI.

Read More

2-28 SBIR & Non-Dilutive Funding Workshop Agenda Set!

University of Maryland Institute for Bioscience & Biotechnology Research, 9600 Gudelsky Drive, Rockville, MD 20850

Register NOW:

  • 8:00 a.m. – Networking and Registration
  • 8:30 a.m. – Welcome
  • 8:35 a.m. – SBIR Funding Opportunities at the National Institutes of Health
    • National Heart, Lung, and Blood Institute
    • National Institute on Aging
    • National Institute on Drug Abuse
    • National Cancer Institute
  • 9:45 a.m. – Partnership Opportunities with NCI Frederick National Lab
  • 10:00 a.m. – BREAK
  • 10:20 a.m. – SBIR Funding Opportunities with the National Science Foundation
  • 11:00 a.m. – BREAK
  • 11:15 a.m. – SBIR Funding Opportunities with USAMRC
  • 11:45 a.m. – Lunch
  • 12:45 p.m. – (1:1 Room Set)
  • 1:00 p.m. – Writing Your Specific Aims Page OR 1:1 Meetings* (available simultaneously)
  • 1:30 p.m. – Writing Your Phase II Commercialization Plan OR 1:1 Meetings* (available simultaneously)
  • 2:00 p.m. – Writing Your Specific Aims Page OR 1:1 Meetings* (available simultaneously)
  • 2:30 p.m. – Writing Your Phase II Commercialization Plan OR 1:1 Meetings* (available simultaneously))
  • 3:00 p.m. – 1:1 Meetings* (NIH only)
  • 4:00 p.m. – Adjourn

Pre-Registration REQUIRED: RSVP by noon, February 26 at charge for entrepreneurs to attend • If seeking 1:1 meeting(s) please include organization(s) in RSVP.

Read More

Johns Hopkins Team to Commercialize Barrett's Esophagus Epigenetic Biomarker Panel | GenomeWeb

A team of researchers led by the Johns Hopkins University of Medicine has developed a methylated epigenetic biomarker panel integrating a sponge-based collection tool and a methylated-bead PCR method that it believes can detect Barrett's esophagus (BE).

Read More

Emergent BioSolutions (EBS) Appoints Seamus Mulligan to Board

Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of Seamus Mulligan to the company’s Board of Directors effective March 19, 2019. Mr. Mulligan was a co-founder and principal investor of Adapt Pharma Ltd. and served as its chairman and CEO from 2014 until 2018, when Adapt was acquired by Emergent.

Read More

A $3.6 million grant will help UMD researchers advance cancer research - Arc Publishing

The National Institute of Health awarded a University of Maryland research center team of scientists $3.6 million to help fund their work on the cells responsible for destroying cancer cells.

Read More

QIAGEN partners with Ares Genetics to advance global fight against antibiotic-resistant pathogens - MarketWatch

QIAGEN N.V. today announced a broad agreement with Ares Genetics, a subsidiary of Curetis N.V. CURE, -0.10% to develop innovative bioinformatics and assay solutions to accelerate research targeting the growing global health challenges posed by antibiotic-resistant bacteria.

Read More

Frederick-based Akonni Biosystems Awarded $3M NIH Phase 2 Award to Develop Low-Cost Tuberculosis Test

Akonni Biosystems, a molecular diagnostics (MDx) company that develops, manufactures, and intends to market advanced MDx systems, today announced receipt of a $3 million, three-year Phase II Small Business Innovation Research (SBIR) contract from the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). Akonni received the Phase I contract in August 2016.

Read More

Kousouris, Bailey Take New Leadership Roles at JHTV – JHTV

Steve Kousouris, who has been serving as Interim Executive Director of Technology Transfer at Johns Hopkins Technology Ventures since June, has assumed this role permanently effective Jan.1. Additionally, Mark Bailey, previously Associate Director of Finance, will assume responsibility for the portfolio that Steve has overseen since 2013 in the capacity of Director, Finance & Administration.

Read More

Kelly M. Schulz, State Secretary of Commerce - I95 Business

Kelly M. Schulz, the newly appointed state secretary of commerce, could be called the secretary of opportunity. Her vision for the state of Maryland is for economic development, job growth, full employment and economic prosperity for all families around the state.

Read More

Is that a robot? Dr. Bear Bot helps care for kids at local hospital. - The Washington Post

“How did you get in the robot?” That was the question a young patient at Children’s National Health System had on Thursday for Dr. Bear Bot.

Read More

18 charts to illustrate US VC in 2018 - PitchBook

Over the past couple of years, the term "record-breaking" has frequently been used to describe the state of venture capital in the US, as the space hits new heights with deal value, mega-rounds and fundraising. In 2018, some of these records reached heights not seen since the dot-com boom.

Read More

Pioneering Physician-Scientist to Receive 2019 Szent-Györgyi Prize for Progress in Cancer Research

The National Foundation for Cancer Research (NFCR) announced today that Steven A. Rosenberg, M.D., Ph.D., of the U.S. National Cancer Institute (NCI) has been selected to receive the 2019 Szent-Györgyi Prize for Progress in Cancer Research. The Prize selection committee awarded Dr. Rosenberg for not only revolutionizing—if not originating—the field now known as cancer immunotherapy but also remaining at its forefront. Chief of the NCI Center for Cancer Research’s surgery branch in Bethesda since 1974, his basic, translational and applied research efforts have contributed immeasurably to groundbreaking advances in therapy and the later development of drugs such as Chiron’s (later Novartis and Prometheus Labs’) Proleukin, Bristol-Myers Squibb’s Yervoy and Gilead’s Yescarta.

Read More

Unlucky 13: Top Clinical Trial Failures of 2018

Nuventra Pharma Sciences, a clinical pharmacology and PK/PD consultancy in Durham, NC, recently offered some insights on why clinical trials fail. In addition to biological considerations—such as pharmacokinetics, pharmacodynamic, and human response to a drug varying from animal models—Nuventra presented a list of reasons that included:

Read More

7 takeaways from HIMSS 2019 - MedCity News

Friday is the official last day of #HIMSS19 in Orlando. The annual healthcare conference, which began on Monday, February 11, was packed full of presentations, panels, products and people.

Read More

Novak Biddle from Roger Novak, Jack Biddle officially closes up shop - Washington Business Journal

The 22-year-old firm has invested in a number of well-known local companies.

Read More

Home | About BHI | BHI News | Programs | Partners | Contact

Copyright © BioHealth Innovation 2017
All Rights Reserved.